$SLBT

Wang Ching-Dong (Chief Executive Officer) purchased 4,545,306 indirectly-held shares of SL Science Holding Ltd (SLBT) at $0.50 ($2.27M total) on 2026-09-29.

NetApp (NTAP) shares dropped 8.2% in pre-market trading despite beating Q1 earnings and revenue estimates. Other stocks moving lower include Ultragenyx (RARE), Methode Electronics (MEI), and Hewlett Packard Enterprise (HPE).

SL Science Holding Limited (SLBT) filed a Master Drug File (MDF) with the FDA for exosomes derived from Gamma Delta T (GDT) cells, which are being developed to treat brain and pancreatic cancers. The filing was made by JY BioMed Co Ltd, an investor and IP rights holder. SLBT's stock closed at $2.64 on Thursday, down to $2.58 in afterhours trading.

SL Science (NASDAQ: SLBT) announced that JY BioMed filed a new FDA Drug Master File (DMF) for GDT cell-derived exosomes, expanding regulatory documentation. This milestone covers exosomes and GDT cells, potentially streamlining future regulatory processes. The exosomes may address delivery challenges in oncology, including crossing the blood-brain barrier for brain cancer treatment.

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

SL Science Holding Limited (Nasdaq: SLBT) said it submitted an FDA Orphan Drug Designation request for its Vdelta2+ Gamma Delta T cell therapy to treat glioblastoma multiforme (GBM). The FDA’s OOPD acknowledged receipt and is reviewing additional files. The company’s licensor JY BioMed will present related preclinical data at WCP 2026.

SL Science Holding Limited (formerly SL BIO Ltd.) began trading on Nasdaq as SLBT in mid-June 2026 after a SPAC merger with Horizon Space Acquisition II Corp. The company develops gamma delta T cell and gene therapies for solid tumors. Shares have swung roughly $3.00–$14.50 (52-week range) with >30% intraday moves; the deal valued equity at ~$5.568B and included a $7.8M PIPE.

SL Science Holding Limited (formerly SL BIO Ltd.) began trading on Nasdaq Global Market under ticker SLBT on June 15 after completing a SPAC merger with Horizon Space Acquisition II Corp. Shares rose ~34% to close at $5.99. The deal valued the combined entity at about $5.6B, funding gamma delta T-cell therapies and other cell/gene and exosome programs.

Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG

SL Science Holding Limited (Nasdaq: SLBT) reported full-year 2025 results for the year ended Dec. 31, 2025. Net revenue fell 35% to about $2.20M from $3.36M, while net loss widened to about $3.82M from $1.19M. The company cited a Taiwan wholesale transition and higher G&A costs. It also said a $7.8M PIPE supported its Nasdaq Global Market listing after a business combination.